These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24379909)

  • 1. Association Between Sustained Glycated Hemoglobin Control and Healthcare Costs.
    Juarez D; Goo R; Tokumaru S; Sentell T; Davis J; Mau M
    Am J Pharm Benefits; 2013; 5(2):59-64. PubMed ID: 24379909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
    Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
    J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes.
    Bansal M; Shah M; Reilly B; Willman S; Gill M; Kaufman FR
    Appl Health Econ Health Policy; 2018 Oct; 16(5):675-684. PubMed ID: 29936685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
    Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
    J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes.
    Shetty S; Secnik K; Oglesby AK
    J Manag Care Pharm; 2005 Sep; 11(7):559-64. PubMed ID: 16137213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a program to improve diabetes care through intensified care management activities and diabetes medication copayment reduction.
    Kogut SJ; Johnson S; Higgins T; Quilliam B
    J Manag Care Pharm; 2012 May; 18(4):297-310. PubMed ID: 22548690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes.
    Ko JJ; Lu J; Rascati K; Stock EM; Juan J; Suh K; Kim Y; Tabor PA; Godley PJ
    J Manag Care Spec Pharm; 2016 Jan; 22(1):32-7. PubMed ID: 27015049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical claim cost impact of improved diabetes control for medicare and commercially insured patients with type 2 diabetes.
    Fitch K; Pyenson BS; Iwasaki K
    J Manag Care Pharm; 2013 Oct; 19(8):609-20, 620a-620d. PubMed ID: 24074007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis.
    Boye KS; Lage MJ; Thieu VT
    Diabetes Ther; 2022 Feb; 13(2):367-377. PubMed ID: 35129822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes.
    Mukherjee J; Sternhufvud C; Smith N; Bell K; Stott-Miller M; McMorrow D; Johnston S
    J Manag Care Spec Pharm; 2016 May; 22(5):449-66. PubMed ID: 27123909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Care Costs, Hospital Admissions, and Glycemic Control Using a Standalone, Real-Time, Continuous Glucose Monitoring System in Commercially Insured Patients With Type 1 Diabetes.
    Gill M; Zhu C; Shah M; Chhabra H
    J Diabetes Sci Technol; 2018 Jul; 12(4):800-807. PubMed ID: 29737202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with poor glycemic control or wide glycemic variability among diabetes patients in Hawaii, 2006-2009.
    Juarez DT; Sentell T; Tokumaru S; Goo R; Davis JW; Mau MM
    Prev Chronic Dis; 2012; 9():120065. PubMed ID: 23017247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population.
    Chung N; Rascati K; Lopez D; Jokerst J; Garza A
    J Manag Care Spec Pharm; 2014 Sep; 20(9):914-9. PubMed ID: 25166290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Costs and Factors Associated with Glycemic Control among Patients with Diabetes in the United Arab Emirates.
    Lee SM; Song I; Suh D; Chang C; Suh DC
    J Obes Metab Syndr; 2018 Dec; 27(4):238-247. PubMed ID: 31089569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study.
    Boye KS; Thieu VT; Lage MJ; Miller H; Paczkowski R
    Adv Ther; 2022 May; 39(5):2208-2221. PubMed ID: 35316502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database.
    Lage MJ; Boye KS
    Curr Med Res Opin; 2020 Sep; 36(9):1441-1447. PubMed ID: 32643451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with higher hemoglobin A1c and type 2 diabetes-related costs: Secondary data analysis of adults 18 to 64 in Texas with commercial insurance.
    Ory MG; Han G; Jani SN; Zhong L; Andreyeva E; Carpenter K; Towne SD; Preston VA; Smith ML
    PLoS One; 2023; 18(9):e0289491. PubMed ID: 37682942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Hemoglobin A1c Management and Prescription Cost Due to Polypharmacy Among Patients With Diabetes in Iran Based on the STEPS Iran 2016 Survey and a Prescription Database: A Multi-level, Cross-sectional National Study.
    Daneshmand M; Jamshidi H; Farjoo MH; Malekpour MR; Ghasemi E; Mortazavi SS; Shati M; Farzadfar F
    Arch Iran Med; 2024 Jan; 27(1):1-7. PubMed ID: 38431954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.